{"entity":{"id":"nct07407933","kind":"trial","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of YL201 and Atezolizumab in small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","summary":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07407933 by MediLink Therapeutics (Suzhou) Co., Ltd., with 118 participants planned, started 2026-03-31 and due to reach its primary completion in 2028-11. Interventions recorded: YL201 and Atezolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07407933","url":"https://clinicaltrials.gov/study/NCT07407933"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["yl201","atezolizumab"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07407933","phase":"1/2","setting":"A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","enrolled":118,"outcomes":[]},"route":"/trials/nct07407933/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}